Celltrion, Inc. Stock Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
Apr. 24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
Sales 2024 * | 3,545B 2.59B | Sales 2025 * | 4,212B 3.08B | Capitalization | 39,768B 29.07B |
---|---|---|---|---|---|
Net income 2024 * | 570B 417M | Net income 2025 * | 1,153B 843M | EV / Sales 2024 * | 11.4 x |
Net Debt 2024 * | 526B 385M | Net cash position 2025 * | 128B 93.3M | EV / Sales 2025 * | 9.41 x |
P/E ratio 2024 * |
78.2
x | P/E ratio 2025 * |
34
x | Employees | - |
Yield 2024 * |
0.21% | Yield 2025 * |
0.23% | Free-Float | 63.31% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jae-Sik Lee
BRD | Director/Board Member | 66 | - |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B | |
+20.18% | 11.72B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock